Cannabis News, Directory and Shopping

Zynerba Pharmaceuticals well-funded for its CBD clinical trials into 2021

111



Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) CEO Armando Anido tells Proactive Investors the Pennsylvania-based biotech has $59.8 million to fund clinical …

source

Comments are closed.